An update on the mechanism of neural stem cell transplantation in the treatment of Alzheimer’s disease

doi:10.16352/j.issn.1001-6325.2023.07.1148

Abstract

Abstract: At present, no effective strategy exists to slow down the progression of Alzheimer’s disease (AD). A deeper understanding of the pathogenesis of AD and the development of new therapeutic approaches are essential. Stem cell transplantation for the treatment of neurodegenerative diseases is currently a research hotspot. Numerous studies have suggested that neural stem cells (NSCs) can differentiate into functional neurons, replace dead neurons, and form synaptic connections with adjacent surviving neurons, thereby achieving a therapeutic effect. In theory, the use of NSCs to replace and restore damaged cholinergic neurons and synapses may provide a new therapeutic option for AD. This review summarizes the recent preclinical research progress of NSC transplantation for the treatment of AD.

Key words: Alzheimer’s disease, cell transplantation, neural stem cells

CLC Number:

R741.05

CHEN Xiaokun, BAO Xinjie, GAO Jun, LI Yongning. An update on the mechanism of neural stem cell transplantation in the treatment of Alzheimer’s disease[J]. Basic & Clinical Medicine, 2023, 43(7): 1148-1151.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.07.1148

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I7/1148

References

[1] Long JM, Holtzman DM.Alzheimer disease: an update on pathobiology and treatment strategies[J]. Cell, 2019, 179: 312-339.
[2] Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease[J]. Lancet, 2021, 397: 1577-1590.
[3] Liu XY, Yang LP, Zhao L.Stem cell therapy for Alzheimer’s disease[J]. World J Stem Cells, 2020, 12: 787-802.
[4] DE Strooper B, Karran E.The cellular phase of Alzheimer’s disease[J]. Cell, 2016, 164: 603-615.
[5] Cribbs DH, Berchtold NC, Perreau V, et al. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study[J]. J Neuroinflammation, 2012, 9: 179. doi:10.1186/1742-2094-9-179.
[6] Macdonald R, Barnes K, Hastings C, et al. Mitochondrial abnormalities in Parkinson’s disease and Alzheimer’s disease: can mitochondria be targeted therapeutically?[J]. Biochem Soc Trans, 2018, 46: 891-909.
[7] Wingo AP, Liu Y, Gerasimov ES, et al. Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer’s disease pathogenesis[J]. Nat Genet, 2021, 53: 143-146.
[8] Yan S, Zheng C, Paranjpe MD, et al. Association of sex and APOE ε4 with brain tau deposition and atrophy in older adults with Alzheimer’s disease[J]. Theranostics, 2020, 10: 10563-10572.
[9] Rasmussen KL, Nordestgaard BG, Frikke-schmidt R, et al. An updated Alzheimer hypothesis: complement c3 and risk of Alzheimer’s disease-a cohort study of 95,442 individuals[J]. Alzheimers Dement, 2018, 14: 1589-1601.
[10] Lim YY, Kalinowski P, PietrzakI RH, et al. Association of β-amyloid and apolipoprotein eε4 with memory decline in preclinical Alzheimer aisease[J]. JAMA Neurol, 2018, 75: 488-494.
[11] Sung PS, Lin PY, Liu CH, et al. Neuroinflammation and neurogenesis in Alzheimer’s disease and potential therapeutic approaches[J]. Int J Mol Sci, 2020, 21:701. doi:10.3390/ijms21030701.
[12] Serrano-pozo A, Das S, Hyman BT. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches[J]. Lancet Neurol, 2021, 20: 68-80.
[13] Madrazo I, Kopyov O, Avila-Rodriguez MA, et al. Transplantation of human neural progenitor cells (NPC) into putamina of parkinsonian patients: a case series study, safety and efficacy four years after surgery[J]. Cell Transplant, 2019, 28: 269-285.
[14] Boese AC, Hamblin MH, Lee JP.Neural stem cell therapy for neurovascular injury in Alzheimer’s disease[J]. Exp Neurol, 2020, 324: 113112. doi:10.1016/j.expneurol.2019.113112.
[15] Nation DA, Sweeney MD, Montagne A, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction[J]. Nat Med, 2019, 25: 270-276.
[16] Zhang Q, Wu HH, Wang Y, et al. Neural stem cell transplantation decreases neuroinflammation in a transgenic mouse model of Alzheimer’s disease[J]. J Neurochem, 2016, 136: 815-825.
[17] Kim JA, Ha S, Shin KY, et al. Neural stem cell transplantation at critical period improves learning and memory through restoring synaptic impairment in Alzheimer’s disease mouse model[J]. Cell Death Dis, 2015, 6: e1789. doi:10.1038/cddis.2015.138.
[18] Moreno-Jimenez EP, Flor-garcia M, Terreros-Roncal J, et al. Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer’s disease[J]. Nat Med, 2019, 25: 554-560.
[19] Sorrells SF, Paredes MF, Cebrian-Silla A, et al. Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults[J]. Nature, 2018, 555: 377-381.
[20] Boldrini M, Fulmore CA, Tartt AN, et al. Human hippocampal neurogenesis persists throughout aging[J]. Cell Stem Cell, 2018, 22: 589-599.
[21] Blurton-Jones M, Kitazawa M, Martinez-Coria H, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease[J]. Proc Natl Acad Sci U S A, 2009, 106: 13594-13599.